MX2012002479A - Nuevos derivados de bencimidazol y su uso como agonistas del receptor x farnesoide. - Google Patents
Nuevos derivados de bencimidazol y su uso como agonistas del receptor x farnesoide.Info
- Publication number
- MX2012002479A MX2012002479A MX2012002479A MX2012002479A MX2012002479A MX 2012002479 A MX2012002479 A MX 2012002479A MX 2012002479 A MX2012002479 A MX 2012002479A MX 2012002479 A MX2012002479 A MX 2012002479A MX 2012002479 A MX2012002479 A MX 2012002479A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- benzimidazole derivatives
- fxr agonists
- new benzimidazole
- new
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09171700 | 2009-09-29 | ||
| PCT/EP2010/064217 WO2011039130A1 (en) | 2009-09-29 | 2010-09-27 | New benzimidazole derivatives and their use as fxr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012002479A true MX2012002479A (es) | 2012-03-26 |
Family
ID=43033176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002479A MX2012002479A (es) | 2009-09-29 | 2010-09-27 | Nuevos derivados de bencimidazol y su uso como agonistas del receptor x farnesoide. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8309581B2 (Direct) |
| EP (1) | EP2483247A1 (Direct) |
| JP (1) | JP5503007B2 (Direct) |
| KR (1) | KR101477872B1 (Direct) |
| CN (1) | CN102574812B (Direct) |
| AU (1) | AU2010303146A1 (Direct) |
| BR (1) | BR112012006986A2 (Direct) |
| CA (1) | CA2772815A1 (Direct) |
| IL (1) | IL218037A0 (Direct) |
| IN (1) | IN2012DN01234A (Direct) |
| MX (1) | MX2012002479A (Direct) |
| WO (1) | WO2011039130A1 (Direct) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE052856T2 (hu) | 2013-09-11 | 2021-05-28 | Inst Nat Sante Rech Med | Eljárások és gyógyászati készítmények Hepatitis B vírus fertõzés kezelésére |
| CN108072684B (zh) * | 2016-11-11 | 2020-06-16 | 中国科学院广州生物医药与健康研究院 | 法尼醇x受体的新配体及其筛选方法和应用 |
| JP7618384B2 (ja) | 2017-02-21 | 2025-01-21 | ジェンフィ | Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ |
| EP3600293A1 (en) | 2017-03-30 | 2020-02-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2888847B1 (fr) * | 2005-07-22 | 2007-08-31 | Sanofi Aventis Sa | Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique |
| BRPI0713946A2 (pt) * | 2006-06-29 | 2012-12-04 | Hoffmann La Roche | compostos, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de fxr, e uso dos compostos |
| DE102007008420A1 (de) | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | Benzimidazolderivate |
| JP5204232B2 (ja) * | 2007-08-27 | 2013-06-05 | エフ．ホフマン−ラ ロシュ アーゲー | Ｆｘｒアゴニストとして使用されるベンゾイミダゾール誘導体 |
| ES2403592T3 (es) * | 2007-11-15 | 2013-05-20 | F. Hoffmann-La Roche Ag | Nuevos derivados de bencimidazol y su empleo como agonsitas del FXR |
| ES2407180T3 (es) * | 2008-09-11 | 2013-06-12 | F. Hoffmann-La Roche Ag | Nuevos derivados de bencimidazol |
| MX2011002914A (es) * | 2008-10-15 | 2011-04-12 | Hoffmann La Roche | Nuevos derivados de bencimidazol. |
-
2010
- 2010-09-20 US US12/885,588 patent/US8309581B2/en not_active Expired - Fee Related
- 2010-09-27 BR BR112012006986A patent/BR112012006986A2/pt not_active Application Discontinuation
- 2010-09-27 JP JP2012531341A patent/JP5503007B2/ja not_active Expired - Fee Related
- 2010-09-27 IN IN1234DEN2012 patent/IN2012DN01234A/en unknown
- 2010-09-27 MX MX2012002479A patent/MX2012002479A/es active IP Right Grant
- 2010-09-27 KR KR1020127010681A patent/KR101477872B1/ko not_active Expired - Fee Related
- 2010-09-27 WO PCT/EP2010/064217 patent/WO2011039130A1/en not_active Ceased
- 2010-09-27 CA CA2772815A patent/CA2772815A1/en not_active Abandoned
- 2010-09-27 EP EP10757215A patent/EP2483247A1/en not_active Withdrawn
- 2010-09-27 CN CN201080043283.8A patent/CN102574812B/zh not_active Expired - Fee Related
- 2010-09-27 AU AU2010303146A patent/AU2010303146A1/en not_active Abandoned
-
2012
- 2012-02-09 IL IL218037A patent/IL218037A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012006986A2 (pt) | 2016-04-12 |
| US8309581B2 (en) | 2012-11-13 |
| EP2483247A1 (en) | 2012-08-08 |
| CA2772815A1 (en) | 2011-04-07 |
| KR101477872B1 (ko) | 2014-12-30 |
| KR20120063536A (ko) | 2012-06-15 |
| CN102574812A (zh) | 2012-07-11 |
| JP5503007B2 (ja) | 2014-05-28 |
| AU2010303146A1 (en) | 2012-04-19 |
| JP2013505977A (ja) | 2013-02-21 |
| IN2012DN01234A (Direct) | 2015-05-15 |
| CN102574812B (zh) | 2016-03-30 |
| HK1171746A1 (zh) | 2013-04-05 |
| IL218037A0 (en) | 2012-04-30 |
| WO2011039130A1 (en) | 2011-04-07 |
| US20110077273A1 (en) | 2011-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN03337A (Direct) | ||
| MX2010005824A (es) | Derivados de aminotiazol. | |
| MX2009003939A (es) | Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes. | |
| TW200608972A (en) | Aryl-pyridine derivatives | |
| MX2010002341A (es) | Derivados de bencimidazol usados como agonistas del receptor x de farnesoide. | |
| MX2011013771A (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17. | |
| SG148178A1 (en) | Indozolone derivatives as 11b-hsd1 inhibitors | |
| PH12012501772A1 (en) | N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as pde10a inhibitors | |
| MX2011012017A (es) | Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl). | |
| MX2010002584A (es) | Derivados de piperidina como agonistas de receptores muscarinicos. | |
| ATE483707T1 (de) | 2-cyclopropylthiazolderivate | |
| SG10201407538WA (en) | Intravenous formulations of neurokinin-1 antagonists | |
| UA102310C2 (ru) | Гетероциклические сульфонамиды, их применение и фармацевтические композиции | |
| MX2009013078A (es) | Derivados de oxadiazol y su uso como potenciadores de los receptores metabotropicos de glutamato - 842. | |
| MX2010003224A (es) | Derivados de biaril sulfonamida. | |
| PH12012501536A1 (en) | Pyrazole compounds as crth2 antagonists | |
| MX2011012639A (es) | Sales de derivados de pirazolon azo sustituidos con biciclo, metodo de preparacion y uso de los mismos. | |
| MX2009010567A (es) | Derivados de imidazolidinona. | |
| MX2008016426A (es) | Derivados de alquilpiridazina como inhibidores de 11 beta hidroxiesteroide deshidrogenasa tipo 1(11b-hsd 1). | |
| IN2012DN00765A (Direct) | ||
| IN2012DN01232A (Direct) | ||
| MX2013002329A (es) | Agonista de receptores de neutrofina y sus usos como medicamentos. | |
| PH12014500499A1 (en) | Triazolopyridine compounds as pde10a inhibitors | |
| MX2010005714A (es) | Compuestos de piridina. | |
| DE602006021539D1 (en) | Morpholine als 5ht2c-agonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |